Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TCT 24: The TAVR UNLOAD Trial
Author(s): Nicolas M Van Mieghem Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) in addition to optimal heart failure therapy (OHFT) compared to OHFT alone in patients with heart failure and moderate aortic stenosis.Dr Nicolas M Van Mieghem (Erasmus University Medical Center, Rotterdam, NL) joins us onsite at TCT Conference to discuss the findings from TAVR UNLOAD (NCT02661451)… View more

Intervention
Innovation and Development in Polymer Heart Valves: A New Era of Transcatheter Aortic Valve Replacement
Author(s): Yu Mao , Fengkai Liu , Xi Chen , et al Added: 6 months ago

Intervention
TCT 24: Pooled Analysis of RHEIA and PARTNER 3
Author(s): Didier Tchétché Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR) in female patients with severe aortic stenosis.Dr Didier Tchétché (Clinique Pasteur, FR) joins us onsite at TCT Conference to discuss the pooled findings from the RHEIA (NCT04160130) and PARTNER 3 (NCT02675114) trials.RHEIA and PARTNER 3 are… View more

Demographic

Intervention
EuroPCR 24: The NOTION-2 Study
Author(s): Ole De Backer Added: 1 year ago
EuroPCR 24 - We are joined onsite by Prof Ole De Backer (Rigshospitalet, DK) to discuss the findings from the NOTION-2 Study. (NCT02825134).NOTION-2 is a randomized, multicenter trial which aimed to investigate transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in 376 patients under 75 years of age with severe aortic valve stenosis in regard to intra-… View more

Intervention
New York Valves 2025
Author(s): Paul Grayburn Added: 10 months ago
Don't miss our late-breaking coverage of New York Valves 2025 Summit, including Expert Interviews offering insights into key data and their future impact on clinical practice. View more

Imaging & Diagnostics

Intervention
Managing LVOT Obstruction in Transcatheter Mitral Replacement with Dr Eleid
Author(s): Mackram F Eleid Added: 6 months ago
Explore advanced strategies for preventing and managing LVOT obstruction in transcatheter mitral valve replacement with Dr Mackram EleidThis presentation, part of Women As One's comprehensive Structural Interventions track, examines of a 90-year-old patient with severe mitral annular calcification, heart failure with preserved ejection fraction, and significant basal septal hypertrophy. Dr Eleid… View more

Intervention
LANDMARK: Myval THV Noninferior to Contemporary Valves
Added: 3 months ago Source:  Transcatheter Academy
One-year outcomes from the LANDMARK trial show the Myval transcatheter heart valve (THV) series is noninferior to contemporary THVs for treating symptomatic severe native aortic stenosis.¹ The results demonstrate comparable clinical efficacy and haemodynamic performance at 1 year.MethodologyLANDMARK (NCT04275726) was a prospective, randomised, open-label, noninferiority trial conducted across 31… View more

Demographic

Intervention
30th Annual Meeting of the ISCP
Author(s): Paula Bouzón Iglesias , Alejandro Gullón de la Roza , Laura Pérez Bacigalupe , et al Added: 1 month ago

Intervention

Prevention & Chronic Conditions
LV Health Does Not Alter Early TAVR Benefit in Aortic Stenosis
Added: 2 months ago Source:  Radcliffe Cardiology
An exploratory analysis of the EARLY TAVR trial has found that the benefits of early transcatheter aortic valve replacement (TAVR) for asymptomatic severe aortic stenosis (AS) are consistent, regardless of baseline left ventricular (LV) health.¹ This suggests that waiting for LV deterioration may not be the optimal strategy for timing intervention.MethodologyThis analysis used data from the EARLY… View more

Imaging & Diagnostics

Intervention
TCT 24: The TRISCEND II Trial
Author(s): Susheel Kodali Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter tricuspid valve replacement (TTVR) compared to optimal medical therapy for patients with severe tricuspid regurgitation (TR).Dr Susheel Kodali (Columbia University Medical Center, New York, US) joins us onsite at TCT Conference to discuss the findings from the TRISCEND II Trial (NCT04482062; Edwards Lifesciences).TRISCEND II is a… View more

Intervention